25	Terasaki.T., Kyo.S., Takakura.M., Maida.Y., Tsuchiya.H., Tomita.K and Inoue.M.	Analysis of telomerase activity and telomere length in bone and soft tissue tumors.	Oncol. Report.			2004(in press)
26	Nishi.H., Nakada.T., Kyo.S., Inoue.M., Shay.JW and Isaka.K.	Hypoxia-inducible factor mediates upregulation of telomerase (hTERT).	Mol.Cell.Biol.			2004(in press)
27	Kawashima.T., Kagawa.S., Kobayashi.N., Shirakiya.Y., Umeoka.T., Teraishi.F., Taki.M., Kyo.S., Tanaka.N and Fujiwara.T.	Telomerase-specific replication selective virotherapy for human cancer.	Clin.Cancer.Res.			2004(in press)
28	Yatabe.N., Kyo.S., Maida.Y., Nishi.H., Nakamura.M., Kanaya.T., Tanaka.M., Isaka.K., Ogawa.S and Inoue.M.	HIF-1-mediated activation of telomerase in cervical cancer cells.	Oncogene.			2004(in press)
29	京 哲、井上正樹.	子宮体癌の発癌分子機構ー分子生物学的機序の解明はどこまで進んだか？ー.	産科と婦人科.			2004(印刷中)
30	京 哲、井上正樹.	子宮内膜増殖症の分子生物学-子宮内膜の発癌分子機構の観点から子宮内膜増殖症を考える-.	臨床と病理.			2004(印刷中)
31	Nakamura.M., Kyo.S., Kanaya.T., Yatabe.N., Maida.Y., Ishida.Y., Fujii.C., Kondo.T., Inoue.M and Mukaida.N.	hTERT-promoter-based tumor specific expression of MCP-1 effectively sensitize cervical cancer cells to a low dose of cisplatin.	Cancer Gene Ther.	11	1-7	2004
32	Kyo.S., Masutomi.K., Maida.M., Kanaya.T., Yatabe.N., Nakamura.M., Takarada.M., Sugawara.I., Murakami.S., Taira.T and Inoue.M.	Significance of immunological detection of hTERT: re-evaluation of expression and localization of hTERT.	Am.J.Pathol.	163	859-867	2003
33	Kanaya T, S Kyo, Maida Y, Yatabe N, Tanaka M, Nakamura M and Inoue M.	Frequent hypermethylation of hMLH1 promoter in normal endometrium of patients with endometrial cancers.	Oncogene.	22	2352-2360	2003
34	Kyo.S., Nakamura.M., Kiyono.T., Maida.Y., Kanaya.T., Tanaka.M.,	Successful immortalization of endometrial glandular cells with normal structural	Am. J. Pathol.	163	2259-2269	2003

	Yatabe.N and Inoue.M.	and functional characteristics.				
35	Tanaka.M., Kyo.S., Kanaya.T., Yatabe.N., Nakamura.M., Maida.Y., Okabe.M and Inoue.M.	Evidence of monoclonal composition of human endometrial epithelial glands and mosaic pattern of clonal distribution in luminal epithelium.	Am.J.Pathol.	163	295-301	2003
36	Nakajima.M., Fujiki.Y., Noda.K., Ohtsuka.H., Ohkuni.H., Kyo.S., Inoue.M., Kuroiwa.Y., Yokoi.T.	Genetic polymorphisms of cyp2c8 in Japanese population.	Drug Metab Dispos.	31	687-690	2003
37	Kanzawa.T., Germano.IM., Kondo.Y., Ito.H., Kyo.S and Kondo.S.	Inhibition of telomerase activity in malignant glioma cells correlates with their sensitivity ti temozolomide.	Br J Cancer.	89	922-929	2003
38	Kawagoe.J., Ohmichi.M., Takahashi.T., Ohshima.C., Mabuchi.S., Takahashi.K., Igarashi.H., Mori-Abe.A., Saitoh.M., Du.B., Ohta.T., Kimura.A., Kyo.S., Inoue.M., Kurachi.H.	Raloxifene inhibits estrogen-induced up-regulation of telomerase activity in a human breast cancer cell line.	J Biol Chem. [Epub ahead of print]			2003
39	Takahashi.A., Higashino.F., Aoyagi.M., Yoshida.K., Itoh.M., Kyo.S., Ohno.T., Taira.T., Ariga.H., Nakajima.K., Hatta.M., Kobayashi.M., Sano.H., Kohgo.T and Shindoh.M.	EWS/ETS fusions activate telomerase in Ewing's tumors.	Cancer Res.	63	8338-8344	2003
40	Takeda.T., Inaba.H., Yamazaki.M., Kyo.S., Miyamoto.T., Suzuki.S., Ehara.T., Kakizawa.T., Hara.M., Degroot.LJ and Hashizume.K.	Tumor-specific gene therapy for undifferentiated thyroid carcinoma utilizing the telomerase reverse transcriptase promoter.	J.Clin.Endcrinol .Metab.	88	3531-3538	2003
41	Ikeda.N., Uemura.H., Ishiguro.H., Hori.M., Hosaka.M., Kyo.S., Miyamoto.K, Takeda.E., Kubota.Y.	Combination treatment with 1alpha,25-dihydroxyvitamin D3 and 9-cis-retinoic acid directly inhibits human telomerase reverse transcriptase transcription	Mol Cancer Ther.	2	739-746	2003

		in prostate cancer cells.				
42	Kanzawa.T., Komata.T., Kyo.S., Germano.IM., Kondo.Y., Kondo.S.	Down-regulation of telomerase activity in malignant glioma cells by p27KIP1.	Int J Oncol.	23	1703-1708	2003
43	京 哲、毎田佳子、中村充宏、金谷太郎、谷田部典之、田中政彰、清野 透、井上正樹.	子宮内膜腺上皮細胞の不死化プロジェクト.	産婦人科の世界.	55	871-882	2003
44	京 哲、井上正樹.	腫瘍マーカー(CA72-4).	産科と婦人科.			2003
45	毎田佳子、京 哲、井上正樹.	妊娠初期絨毛のテロメレース活性ー妊娠の進行に伴う推移についてー.	産婦人科の世界.	55	1315-1322	2003
46	T.Kita., Y.Kikuchi., M.Takano., M.Suzuki., M.Oowada., R.Konno., K.Yamamoto., H.Inoue., H.Seto., T.Yamamoto., K.Shimizu.	The effect of single weekly paclitaxel in heavily pretreated patients with recurrent or persistent advanced ovarian cancer.	Gynecol Oncol.	92	813-818	2004
47	Gotoh.T., Hayashi.N., Takeda.S., Itoyama.S., Takano.M., Kikuchi.Y.	Synchronous mucinous adenocarcinoma of the endometrium and mucinous cystadenoma of bilateral ovaries presenting during fertility therapy.	Int J Gynecol Cancer.	14	169-171	2004
48	K.Yamamoto., S.Oogi., H.Inoue., K.Kudoh., T.Kita., Y.Kikuchi.	Chronic administration of single weekly paclitaxel in heavily pretreated ovarian cancer patients.	Current Medicinal Chemistry.	11	425-428	2004
49	菊池義公、工藤一弥.	DNA チップ法 —遺伝子診断の新展開— 2.各論 固形腫瘍.	Medical Technology.	31	40-46	2003
50	菊池義公.	卵巣癌の薬剤耐性に関わる因子の同定.	産婦人科治療.	86	874	2003
51	Furuya.K., Murakami.M., Makimura.N., Matsuda.H., Ikou.K., Saito.K., Kawakami.Y., Shibazaki.T., Fukui.U., Mizumoto.Y., Tokuoka.S., Nagata.I., Kikuchi.Y.	Immunological and endocrinological studies on lymphocyte subpopulation and medical treatment for infertility in patients with endometriosis.	Mol Cell Endocrinol.	202	195-199	2003
52	Machida.S., Ohwada.M., Fujiwara.H., Konno.R., Takano.M., Kita.T., Kikuchi.Y., Komiyama.S., Mikami.M., Suzuki.M.	Phase I study of combination chemotherapy using irinotecan hydrochloride and nedaplatin for advanced or recurrent cervical cancer.	Oncology.	65	102-107	2003

53	Sawada.M., Tsuda.H., Kimura.M., Okamoto.S., Kita.T., Kasamatsu.T., Yamada.T., Kikuchi.Y., Honjo.H., Matsubara.O.		Cancer Sci	94	986-991	2003
54	Kikuchi.Y., Tode.T., Hirata.J., Nakata.H., Kita.T.	Clinical usefulness of Korean red ginseng in postmenopausal women with severe climacteric disturbance.	J Ginseng Res.	27	98-102	2003
55	Takano.M., Shibasaki.T., Sato.K., Aida.S., Kikuchi.Y.	Malignant mixed Mullerian tumor of the uterine corpus with alpha-fetoproteinproducing hepatoid adenocarcinoma component.	Gynecol Oncol.	91	444-448	2003
56	Fujimoto.J., Nakagawa.Y., Sato.E., Sakaguchi.H., Tamaya.T.	Clinical implications of estrogen related receptor (ERR) in uterine endometral cancers.	Eur J Cancer.			2004 (in press)
57	Sakaguchi.H., Fujimoto.J., Aoki.I., Tamaya.T.	Clinical implications of expression of ETS-1 related to angiogenosis in ovarian endometrioma.	Fertil Steril.			2004 (in press)
58	Fujimoto.J., Aoki.I., Toyoki.H., Khatun.S., Sato.E., Sakaguchi.H., Tamaya.T.	Clinical implications of expression of ETS-1 related to angiogenosis in metastatic lesions of ovarian cancers.	Oncology.			2004 (in press)
59	Sun.WS., Fujimoto.J., Tamaya.T.	Clinical implications of coexpression of growth arrested-specific gene 6 and receptor tyrosine kinase Axl and Sky in human ovarian cancers.	Oncology.			2004 (in press)
60	Sun.WS., Fujimoto.J., Tamaya.T.	Clinical implications of coexpression of growth arrested-specific gene 6 and receptor tyrosine kinase Axl and Sky in human uterine leiomyoma.	Mol Hum Reprod.	11	701-707	2003
61	Khatun.S., Fujimoto.J., Toyoki.H., Tamaya.T.	Clinical implications of expression of ETS-1 related to angiogenosis in ovarian cancers.	Cancer Sci (Jpn J Cancer Res).	1	769-773	2003
62	Sun.WS., Fujimoto.J.,	Coexpression of growth	Ann Oncol.	14	898-906	2003

	Tamaya.T.	arrested-specific gene 6 and receptor tyrosine kinase AXl and Sky in human uterine endometrial cancers.				
63	Fujimoto.J., Aoki.I., Toyoki.H., Khatun.S., Sato.E., Tamaya.T.	Expression of ETS-1 related to angiogenesis in uterine endometrium dring the menstrual cycle.	J Biomed Sci.	10	320-327	2003
64	Aoki.I., Fujimoto.J., Tamaya.T.	Effect of various steroids on platelet-derived endothelial cell growth factor (PD-ECGF) and its mRNA expression in uterine endometrial cancer cells.	J Steroid Biochem Mol Biol.	84	217-222	2003
65	Y.Sato., Y.Maeda., T.Sasatomi., M.Takahashi., Y.Une., M.Kondo., T.Shinohara., N.Hida., K.Katagiri., K.Sato., A.Yamada, H. Yamana, K. Itoh, and S. Todo.	A phase I trial of CTL-purecursor-oriented peptide vaccine for colorectal carcinoma patients.	Br. J. Cancer.			2004(in press)
66	K.Fukuda., Y.Takao., Y.Miyazaki., K.Itoh and A.Yamada.	Natural antibodies reactive to self peptides which had been identified as cytotoxic T-lymphocyte (CTL)-directed tumor antigens.	Immunobiology.			2004.(in press)
67	M.Noguchi., K.Itoh., S.Suekane., A.Yao., N.Suetsugu., K.Katagiri., A.Yamada., H.Yamana., S.Noda.	Phase I trial of patient-oriented vaccination in HLA-A2 positive patients with metastatic hormone refractory prostate cancer.	Cancer Sci.	95	77-84	2004
68	M.Koga., N.Komatsu., S.Shichijo., K.Itoh and A.Yamada.	Analysis of cellular localization of SART3 tumor antigen by newly established monoclonal antibody. Heterotopic expression of SART3 tumor antigen on the surface of B-lineage leukemic cells.	Oncol. Reports.	11	785-789	2004
69	W.Kumamaru., S.Nakamura., T.Kadena.,	T cell receptor V• gene usage by T cells reactive	Int. J. Cancer.	108	686-695	2004

	A.Yamada., E.Kawamura., M.Sasak.i, Y. Ohyama., T.Toyoshima., J.Hayashida., K.Itoh and K. Shirasuna.	with the tumor rejection antigen SART-1 in oral squamous cell carcinoma.				
70	N.Tsuda., K.Mochizuki., M.Harada., A.Sukehiro., K.Kawano., A.Yamada., K.Ushijima., T.Sugiyama., T.Nishida., H.Yamana., K.Itoh and T.Kamura.	Vaccination with pre-designated or evidence-based peptides for patients with recurrent gynecologic cancers.	J. Immunother.	27	60-67	2004
71	Y.Sato., H.Shomura., Y.Maeda., T.Mine., Y.Une., Y.Akasaka., M.Kondo., S.Takahashi., T.Shinohara., K.Katagiri., M.Sato., S.Okada., K.Matsui., A.Yamada., H.Yamana., K.Itoh and S.Todo.	Immunological evaluation of peptide vaccination for patients with gastric cancer based on pre-existing cellular response to peptide.	Cancer Sci.	94	802-808	2003
72	S.Ohkouchi., N.Kawamoto., F.Sakanashi., S.Shichijo., Y.Saijo., T.Nukiwa., K.Itoh and A.Yamada.	Identification of cytotoxic T lymphocyte-directed epitope encoded by an intron of putative tumor suppresser gene Testin of the common fragile site 7G region at 7q31.2: Peptide vaccine candidate for HLA-B52$^+$ and -62$^+$ cancer patients.	Eur. J. Immunol.	33	2964-2973	2003
73	N.Ikewaki., A.Yamada and H.Inoko.	Depolymerization of actin filament by cytochalasin E induces interleukin-8 production and up-regulates CD54 in the Hela epithelial cell line.	Microbiol. Immunol.	47	775-783	2003
74	T.Mine., R.Gouhara., N.Hida., N.Imai., K.Azuma., T.Rikimaru., K.Katagiri., M.Nishikori., A.Sukehiro., M.Nakagawa., A.Yamada., H.Aizawa., K.Shirouzu., K.Itoh and H.Yamana.	Immunological evaluation of CTL precursor-oriented vaccines for advanced lung cancer patients.	Cancer Sci.	94	548-556	2003
75	S.Tanaka., M.Harada., T.Mine., M.Noguchi., R.Gohara., K.Azuma.,	Peptide vaccination for patients with melanoma and other types of cancers	J.Immunother.	26	357-366	2003

	M.Tamura., A.Yamada., A.Morinaga., M.Nishikori., K.Katagiri., K.Itoh., H.Yamana and T.Hishimoto.	based on pre-existing peptide-specific cytotoxic T lymphocyte precursors in the periphery.				
76	M.Noguchi., K.Kobayashi., N.Suetsugu., K.Tomiyasu., S.Suekane., A.Yamada., K.Itoh and S.Noda.	Induction of cellular and humoral immune responses to tumor cells and peptides in HLA-A24 positive hormone-refractory prostate cancer patients by peptide vaccination.	Prostate.	57	80-92	2003
77	N.Kawamoto., S.Ohkouchi., T.Maeda., S.Tanaka., T.Hashimoto., S.Saijo., Y.Saijo., S.Shichijo., K.Itoh and A.Yamada.	IgG reactive to CTL-directed epitope peptides is either lacking or unbalanced in atopic dermatitis patients.	Tissue Antigens.	61	352-361	2003
78	A.Yamada., K.Kawano., M.Koga., S.Takamori., M.Nakagawa and K.Itoh.	Gene and peptide analyses of newly defined lung cancer rejection antigens recognized by HLA-A2402-restricted tumor-specific cytotoxic T.	Cancer Res.	63	2829-2835	2003
79	M.Koga., S.Shichijo., A.Yamada., J.Ashihara., H.Sawamizu., J.Kusukawa and K.Itoh.	Identification of ribosomal proteins S2 and L10a as tumor-rejection antigens recognized by HLA-A26-restricted CTL.	Tissue Antigens.	61	136-145	2003

Ⅲ. 研究成果の刊行に関する一覧表

書籍

No.	著者氏名	論文タイトル名	書籍全体の編集者名	書 籍 名	出版社名	出版地	出版年	ページ
1	Ueoka.Y., Kato.K and Wake.N.	Hepatocyte growth factor modulates motility and invasiveness of ovarian carcinoma via Ras mediated pathway.		Molecular and cellular endocrinology.	Elsevier Science Ireland Ltd.	Ireland	2003	202:80-88
2	Kyo.S., Kanaya.T and Inoue.M.	Role of hMLH1 gene hypermethylation in endometrial carcinogenesis.		In: Kuramoto H, Nishida M (Eds.)	Cell and Molecular Biology of Endometrial Carcinoma.		2003	232-244
3	菊池義公.	殺細胞効果の分類と作用機序 白金化合物	有吉 寛、上田龍三、西条長宏、峠 哲哉、福岡正博	臨床腫瘍学	癌と化学療法社.		2003	224-232
4	H.Hiramatsu., S.Okamoto., T.Kita., Y.Kikuchi. H.	Relationship between HER-2/neu gene status and chemosensitivity of human endometrial cancer cell lines.	Kuramoto, M.Nishida (Eds.).	Cell and molecular biology of endometrial carcinoma.	Springer-Verlag.		2003.	295-312
5	A.Yamada., H.Yamana., K.Itoh.	Peptide-based vaccines for cancer immunotherapy.	In "Current Topics in Peptide & Protein Research".	Research Trend, India.			2004	241-247